Description

Mirko Beljanski’s interest in strengthening the immune system led him to develop a natural product that stimulates the production of white blood cells (WBCs) and platelets—cells that are vital for immunity and for a healthy clotting reaction in blood.*
His work as a biochemist made him aware that DNA duplication, the first step of cell division—requires small RNA fragments that function as primers for DNA synthesis. Beljanski realized that a shortage of these RNA primers in bone marrow stem cells where WBC and platelets originate, could be a primary cause of low WBC counts (neutropenia) and low platelet counts (thrombocytopenia). He prepared short fragments of RNA in the laboratory and showed that these RNAs did indeed specifically stimulate proliferation of white blood cells and platelets.1,2*
More recently, a clinical trial at Cancer Treatment Centers of America demonstrated that these RNA fragments helped maintain normal WBCs and platelets in patients receiving chemotherapy—for which neutropenia and thrombocytopenia are common side effects.3 This is a breakthrough result that enabled the patients to complete their treatment without interruption, dose reduction, or platelet transfusion.*
Beljanski’s RNA fragments have been formulated in Immunobel-Pro™ and are now available to healthcare professionals for their patients who suffer from low WBC and platelet counts. The RNAs naturally restore normal levels of these cells without any negative side effects at all.*
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Beljanski M, Plawecki M, Bourgarel P, Beljanski MS. Nouvelles substances (R.L.B.) actives dans la leucopoïèse et la formation des plaquettes. Bull. Acad. Nat. Méd. 1978;(162)6:475-781.
Beljanski M. Overview: BLRs as Inducers of In Vivo Leucocyte and Platelet Genesis. Deutsche Zeitschrift für Onkologie. 1992(24)2:41-46.
Levin RD, Daehler M, Grutsch Jf, Hall JL, Gupta D, et al. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC Cancer. 2010;10:565.